Last reviewed · How we verify
SHR6508 plus oral placebo tablets
SHR6508 is a small molecule drug that targets the molecular target.
SHR6508 is a small molecule drug that targets the molecular target. Used for unknown.
At a glance
| Generic name | SHR6508 plus oral placebo tablets |
|---|---|
| Sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| Drug class | small molecule |
| Target | unknown |
| Modality | Small molecule |
| Therapeutic area | unknown |
| Phase | Phase 3 |
Mechanism of action
SHR6508 works by binding to the molecular target, which results in the desired therapeutic effect.
Approved indications
- unknown
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: